# Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial

> **NCT04375657** · PHASE2 · RECRUITING · sponsor: **Intervene Immune, Inc.** · enrollment: 85 (estimated)

## Conditions studied

- Epigenetic Aging
- Immunosenescence

## Interventions

- **COMBINATION_PRODUCT:** TRIIM Treatment
- **COMBINATION_PRODUCT:** Active Control

## Key facts

- **NCT ID:** NCT04375657
- **Lead sponsor:** Intervene Immune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-23
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04375657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04375657, "Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04375657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*